Amgen (NASDAQ: AMGN) and UCB presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than TeriparatideOctober 12, 2015 4:01 PM Radius Health (RDUS), Dyax Corp (DYAX) Highlighted as Speculative Takeover PlaysOctober 12, 2015 12:06 PM Eli Lilly's (LLY) Hold Rating Maintained at Deutsche Bank (MRK) (AMGN)October 12, 2015 10:14 AM Lilly's (LLY) CETP Inhibitor Disappointment Seen as Positive for Esperion (EPSR) and PCSK-9, Says RBC (REGN) (AMGN) (SNY) (MDCO) (MRK)October 12, 2015 9:13 AM